In	IN
terms	NNS
of	IN
the	DT
global	JJ
market	NN
,	,
India	NNP
currently	RB
holds	VBZ
a	DT
modest	JJ
1	CD
-	SYM
2	CD
%	NN
share	NN
,	,
but	CC
it	PRP
has	VBZ
been	VBN
growing	VBG
at	IN
approximately	RB
10	CD
%	NN
per	IN
year[27	NN
]	-RRB-
.	.

India	NNP
gained	VBD
its	PRP$
foothold	NN
on	IN
the	DT
global	JJ
scene	NN
with	IN
its	PRP$
innovatively	RB
-	HYPH
engineered	VBN
generic	JJ
drugs	NNS
and	CC
active	JJ
pharmaceutical	JJ
ingredients	NNS
(	-LRB-
API	NNP
)	-RRB-
,	,
and	CC
it	PRP
is	VBZ
now	RB
seeking	VBG
to	TO
become	VB
a	DT
major	JJ
player	NN
in	IN
outsourced	JJ
clinical	JJ
research	NN
as	RB
well	RB
as	IN
contract	NN
manufacturing	NN
and	CC
research	NN
.	.

There	EX
are	VBP
74	CD
U.S.	NNP
FDA	NNP
-	HYPH
approved	VBN
manufacturing	NN
facilities	NNS
in	IN
India	NNP
,	,
more	JJR
than	IN
in	IN
any	DT
other	JJ
country	NN
outside	IN
the	DT
U.S	NNP
,	,
and	CC
in	IN
2005	CD
,	,
almost	RB
20	CD
%	NN
of	IN
all	DT
Abbreviated	NNP
New	NNP
Drug	NNP
Applications	NNP
(	-LRB-
ANDA	NNP
)	-RRB-
to	IN
the	DT
FDA	NNP
are	VBP
expected	VBN
to	TO
be	VB
filed	VBN
by	IN
Indian	JJ
companies[21,27	NN
]	-RRB-
.	.

Growth	NN
in	IN
other	JJ
fields	NNS
notwithstanding	JJ
,	,
generics	NNS
are	VBP
still	RB
a	DT
large	JJ
part	NN
of	IN
the	DT
picture	NN
.	.

